Cardiovascular Device Revenues Will More Than Double By 2025, A New Visiongain Study Forecasts

14 September 2018
Pharma

A new report by visiongain predicts that revenue from cardiovascular medical devices will more than double by 2025. That work forecasts the cardiovascular devices market will achieve overall sales of $51bn in 2015. Cardiac rhythm management devices will continue to account for the biggest proportion of that market. Growth variations between the segments are expected to occur from 2015 to 2025, with cardiac prosthetic devices likely to outperform the other product classes for revenue growth.

Those sales predictions and others appear in Cardiovascular Medical Devices: World Market, Industry, Trends and Revenue Forecasts 2015-2025, published in November 2015. Visiongain is a business information publisher and consultancy in London, UK. Its purpose is helping companies and other organisations to assess the future of industries and markets.

That report’s author said: “The cardiology devices sector is a mature market, but still there are several segments likely to experience medium to high growth during the next 10 years. Developments in the healthcare sector in developing economies boost the demand for medical devices, which compensates for moderate sales in Europe and Japan. The overall cardiology devices market is expected to achieve sales growth, with newly approved, innovative devices likely to generate high revenues. Much of the market’s development is linked to the increasing prevalence of heart disorders worldwide and aging populations. However the prominence of the cardiovascular devices market very much depends on country-specific reimbursement regulations, along with favourable economic conditions.”

Mergers and acquisitions gained momentum in the past two years, showing the medical device industry’s move towards consolidation. Cardiac device manufacturers are competing to introduce novel technologies with proven cost-effectiveness, aiming to gain better market access for treating heart conditions and other cardiovascular diseases. Research and development efforts progress, with almost 30 FDA approvals of cardiovascular devices in 2014 and 2015.

The report shows overall world revenue for that market to 2025. It also gives revenue predictions from 2015 to 2025 at world level for four main segments:

• Cardiac rhythm management • Prosthetic devices • Interventional cardio products • Monitoring and diagnostics.

That work also shows world revenue forecasts from 2015 to 2025 for another 11 applications:

• Cardiac pacemakers • Defibrillators • Ventricular assist devices • Cardiac stents • Heart valves • Catheters • Angioplasty balloons • Guidewires • Accessories • Electrocardiography • Cardiac output monitoring.

Visiongain also gives sales forecasts from 2015 to 2025 for the US, Japan, Germany, France, the UK, Italy, Spain, China, India, Russia and Brazil. The study’s forecasting comes with discussions, including SWOT and STEP analyses. The work includes profiles of leading companies: Abbott Laboratories, Biotronik, Boston Scientific, Edwards Lifesciences, Medtronic, the Sorin Group and St. Jude Medical.

Cardiovascular Medical Devices: World Market, Industry, Trends and Revenue Forecasts 2015-2025 adds to visiongain’s range of analytical reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, medical devices, biotechnologies and outsourced services.

Recent News

Visiongain Publishes Medical Device Contract Manufacturing Market Report 2021-2031

Increasing demand for medical products in developing as well developed economies coupled with rising ageing population is expected to open new opportunities for medical device contract manufacturing industry over the forecast period.

01 December 2020

Read

Visiongain Publishes Virus Testing Diagnostic Kits Market Report 2021-2031

With the growing burden of rare diseases around the world, there has been a rise in the requirement for proper diagnosis as well as full proof treatment positions for various chronic diseases. With increasing awareness regarding symptoms of various terminal illnesses, the diagnosis rates have been improving in developing countries such as China, India, Japan, Brazil, and other southeast Asian countries.

01 December 2020

Read

Visiongain Publishes RNA Analysis/Transcriptomics Market Report 2020-2030

Rising preference for personalised medicine in developed as well developing economies coupled with increasing investment by biotechnological and pharmaceutical companies for drug discovery is expected to increase RNA analysis/transcriptomics market concentration over the forecast period. In order to increase the reliability and success rate of the drug production process.

30 November 2020

Read

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever